insights_auto
Why is BIIB34 down 2.01%?
Dive Deeperchevron_right
BIIB34:BVMF
Biogen Inc BDR
R$184.49
arrow_downward
-2.01%(-3.79) 1D
Oct 5, 4:56:00 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Open
R$185.82
High
R$185.82
Low
R$184.49
Mkt. cap
33.04B
Avg. vol.
1.00
Volume
185.00
52-wk high
R$191.00
52-wk low
R$128.69
Shares outstanding
147.75M
No. of employees
8K
Open
R$185.82
High
R$185.82
Low
R$184.49
Mkt. cap
33.04B
Avg. vol.
1.00
Volume
185.00
52-wk high
R$191.00
52-wk low
R$128.69
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
Kalkine Media
·
1 hour ago
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4
AD HOC NEWS
·
3 hours ago
Biogen stock gains 1.56 percent as litifilimab data reach Week 52
BioSpace
·
3 hours ago
Biogen’s big lupus bet gets boost from new durability data for skin disease
AD HOC NEWS
·
8 hours ago
Biogen reports litifilimab data and Jefferies keeps Buy on Biogen stock
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com